Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Tirzepatide (Zepbound / Mounjaro) targets both GLP-1 and GIP receptors, offering a dual-action approach that clinical trials show may lead to even greater weight loss
The phase 2 NEJM-published data showing up to 20% weight loss at 52 weeks with monthly injections and GI side effects concentrated at the first dose are
Patients with high-sensitivity variants benefit from lower starting doses, oral formulations, or dual-compound protocols, reducing stomach pain incidence and improving long-term treatment adherence
Theres no prescription, no onboarding, and no medical intake
CONFLICTS OF INTEREST Young Min Cho received research grants from Daewoong Pharmaceuticals and Sanofi, and consultation fees from LG Chemical
US$ 24.20
US$ 24.93
US$ 20.40
US$ 23.91
US$ 21.62
US$ 27.05
US$ 21.41
US$ 23.69
